Advances in pump technology: Insulin patch pumps, combined pumps and glucose sensors, and implanted pumps

Diabetes and Metabolism

Volumn 37, Issue SUPPL. 4, 2011, Pages

  Schaepelynck, P ^a   Darmon, P ^a   Molines, L ^a   Jannot Lamotte, M F ^a   Treglia, C ^a   Raccah, D ^a  

^a Hopitaux Sud AP HM   (France)

Author keywords

Coupled sensor pump; Implanted insulin pump; Insulin patch pump; Review

Indexed keywords

CARBOHYDRATE; GLUCOSE; INSULIN; PEPTIDE; PROTEIN;

ABSENTEEISM; ARTICLE; ARTIFICIAL PANCREAS; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; CANNULA; DIALYSIS; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP; TUBE;

ANALYSIS OF VARIANCE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS, IMPLANTABLE; INSULIN INFUSION SYSTEMS; MALE; QUALITY OF LIFE;

EID: 84855182418     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/S1262-3636(11)70972-7     Document Type: Article

References (61)

1. Misso M.L., Egberts K.J., Page M., O'Connor D., Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010, 20(1). CD005103.
2. Clavel S., Guerci B., Hanaire H., Lassmann-Vague V., Leroy R., Loeuille G.A., et al. Quand et comment traiter un patient diabétique par pompe à insulin externe? Référentiel de la Société Francophone du Diabète 2009. Médecine et maladies métaboliques 2009, 3. Hors-série n° 2.
3. Skladany M.J., Miller M., Guthermann J.S., Ludwig C.R. Patch-pump technology to manage type 2 diabetes mellitus: hurdles to market acceptance. J Diabetes Sci Technol 2008, 2:1147-1150.
4. Selam J.L. Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol 2010, 4:505-513.
5. Anhalt H., Bohannon N.J. Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technol Ther 2010, 12(Suppl 1):S51-S58.
6. Zisser H., Jovanovic L. OmniPod Insulin Management System: patient perceptions, preferences and glycemic control. Diabetes Care 2006, 29:2175.
7. Lane W.S., Weinrib S.L., Rappaport J.M., Przestrzelski T. A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance. Endocr Pract 2010, 16:778-784.
8. Schütt M., Kern W., Krause U., Busch P., Dapp A., Grziwotz R., et al. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes 2006, 114:384-388.
9. Kerr D., Olateju T. Pascal's wager: combining continuous glucose monitoring and continuous subcutaneous infusion. Diabetes Technol Ther 2010, 12:S43-S50.
10. Hirsch I.B., Abelseth J., Bode B.W., Fischer J.S., Kaufman F.R., Mastrototaro J., et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008, 10:377-383.
11. Raccah D., Sulmont V., Reznik Y., Guerci B., Renard E., Hanaire H., et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the Real trend study. Diabetes Care 2009, 32:2245-2250.
12. Bergenstal R.M., Tamborlane W.V., Ahmann A., Buse J.B., Dailey G., Davis S.N., et al. Effectiveness of sensoraugmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010, 363:311-320. For the STAR 3 study group.
13. Buse J.B., Dailey G., Ahmann A.A., Bergenstal R.M., Green J.B., Peoples T., et al. Baseline predictors of A1c reduction in adults using sensoraugmented pump therapy or multiple daily injection therapy: the STAR 3 experience. Diabetes Technol Ther 2011, 13:601-606.
14. Conget I., Battelino T., Gimenez M., Gough H., Castaneda J., Bolinder J. The SWITCH study (Sensing With Insulin pump Therapy to Control HbA1c): Design and methods of a randomized controlled crossover trial on sensor-augmented insulin pump efficacy in type 1 diabetes suboptimally controlled with pump therapy. Diabetes Technol Ther 2011, 13:49-54. on behalf of the SWITCH study group.
15. Continuous Glucose Monitoring an intensive treatment of type 1 diabetes. N Engl J Med 2008, 359:1464-1476. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring study group.
16. Schaepelynck P., Rocher L., Hanaire H., Chaillous L., Renard E., Sola A., et al. Patient- or physician-driven Continuous Glucose Monitoring improves control and quality of life in poorly-controlled type 1 diabetic patients on intensified insulin therapy: a one-year multicenter study. Diabetes 2011, 60(Suppl 1):236-240. for the EVADIAC Sensor study group.
17. Garg S.K., Voemle M.K., Beatson C.R., Miller H.A., Crew L.B., Freson B.J., et al. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care 2011, 34:574-579.
18. Battelino T., Phillip M., Bratina N., Nimri R., Oskarson P., Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011, 34:795-800.
19. Buckingham B., Block J., Burdick J., Kalajian A., Kollman C., Choy M., et al. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther 2005, 7:440-447.
20. Davis E.A., Keating B., Byrne G.C., Russell M., Jones T.W., Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997, 20:22-25.
21. Buckingham B., Cobry E., Clinton P., Gage V., Caswell K., Kunselman E., et al. Preventing hypoglycemia using preventing alarm algorithms and insulin pump suspension. Diabetes Technol Ther 2009, 11:93-97.
22. Buckingham B., Chase P., Dassau E., Cobry E., Clinton P., Gage V., et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care 2010, 33:1013-1017.
23. Dassau E., Cameron F., Lee H., Bequette B.W., Zisser H., Jovanovic L. Real-time hypoglycemia prediction suite using continuous glucose monitoring: a safety net for the artificial pancreas. Diabetes Care 2010, 33:1249-1254.
24. Keenan D.B., Cartaya R., Mastrototaro J. Accuracy of a new real-time Continuous Glucose Monitoring algorithm. J Diabetes Sci Technol 2010, 4:111-118.
25. Choudhary P., Shin J., Wang Y., Evans M.L., Hammond P.J., Kerr D., et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011, 34:2023-2025.
26. Danne T., Kordonouri O., Holder M., Haberland H., Golembowski S., Remus K., et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011, [Epub ahead of print] PubMed PMID: 21827318 Aug 9].
27. Pickup J. Semi-closed-loop insulin delivery systems: early experience with low-glucose insulin suspend pumps. Diabetes Technol Ther 2011, 13:695-698.
28. Wredling R., Liu D., Lins P.E., Adamson U. Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin-dependent diabetic patients with unsatisfactory long-term glycaemic response to continuous subcutaneous insulin infusion. Diabetes Metab 1991, 17:456-459.
29. Nelson J.A., Stephen R., Landau S.T., Wilson D.E., Tyler F.H. Intraperitoneal insulin administration produces a positive portal-systemic blood insulin gradient in unanesthetized, unrestrained swine. Metabolism 1982, 31:969-972.
30. Selam J.L., Raymond L., Jacquemin J.L., Orsetti A., Richard J.L., Mirouze J. Pharmacokinetics of insulin infused intra-peritoneally via portable pumps. Diabetes Metab 1985, 11:170-173.
31. Schade D.S., Eaton R.P., Davis T., Akiya F., Phinney E., Kubica R., et al. The kinetics of peritoneal insulin absorption. Metabolism 1981, 30:149-155.
32. Schade D.S., Eaton R.P., Friedman N.M., Spencer W.J. Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabeticman. Diabetologia 1980, 19:35-39.
33. Schaepelynck Belicar P., Vague P., Lassmann-Vague V. Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumps. Diabetes Metab 2003, 29:344-348.
34. Oskarsson P.R., Lins P.E., Backman L., Adamson U.C. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients. Diabetes Metab 2000, 26:118-124.
35. One-year trial of a remote-controlled implantable infusion system in type 1 diabetic patients. Lancet 1988, I:866-869. Point study group.
36. Saudek C.D., Selam J.L., Pitt H.A., Waxman K., Rubio M., Jeandidier N., et al. A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med 1989, 321:574-579.
37. Selam J.L., Micossi P., Dunn F.L., Nathan D.M. Clinical trial of programmable implantable insulin pumps for type 1 diabetes. Diabetes Care 1992, 15:877-885.
38. Broussolle C., Jeandidier N., Hanaire-Broutin H. French multicenter experience with implantable insulin pumps. Lancet 1994, 343:514-515. for the Evadiac study group.
39. Hanaire-Broutin H., Broussolle C., Jeandidier N., Renard E., Guerci B., Haardt M.J., et al. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM: a multicenter study. Diabetes Care 1995, 18:388-392. the EVADIAC study group.
40. Jeandidier N., Selam J.L., Renard E., Guerci B., Lassman-Vague V., Rocher L., et al. Decreased severe hypoglycaemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Diabetes Care 1996, 19:780. For the Evadiac study group.
41. Gin H., Renard E., Melki V., Boivin S., Schaepelynck-Belicar P., Guerci B., et al. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Diabetes Metab 2003, 29:602-607. the EVADIAC study group.
42. Schaepelynck P., Renard E., Jeandidier N., Hanaire H., Fermon C., Rudoni S., et al. A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patients. Diabetes Technol Ther 2011, 13:657-660. On behalf of the EVADIAC Group.
43. De Vries J.H., Eskes S.A., Snoek F.J., Pouwer F., Van Ballegooie E., Spijker A.J., et al. Continuous intraperitoneal insulin infusion in patients with "brittle" diabetes: favourable effects on glycaemic control and hospital stay. Diabet Med 2002, 19:496-501.
44. Selam J.L., Raccah D., Jeandidier N., Lozano J.L., Waxman K., Charles M.A. Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care 1992, 15:53-58.
45. Haardt M.J., Selam J.L., Slama G., Bethoux J.P., Dorange C., Mace B., et al. A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes. Diabetes Care 1994, 17:847-851.
46. Saudek C.D., Duckworth W.C., Giobbie-Hurder A., Henderson W.G., Henry R.R., Kelley D.E., et al. Implantable insulin pumps vs. multiple dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. JAMA 1996, 276:1322-1327.
47. Logtenberg S.J., Kleefstra N., Houweling S.T., Groenier K.H., Gans R.O., Bilo H.J. Health-related quality of life, treatment satisfaction, and costs associated with intraperitoneal versus subcutaneous insulin administration in type 1 diabetes: a randomized controlled trial. Diabetes Care 2010, 33:1169-1172.
48. Belicar P., Lassmann-Vague V. Local adverse events associated with long-term treatment by implantable insulin pumps. Diabetes Care 1998, 21:325-326. the EVADIAC study group.
49. Renard E., Rostane T., Carriere C., Marchandin H., Jacques-Apostol D., Lauton D., et al. Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pumppocketseromas. Diabetes Metab 2001, 27:62-65.
50. Olsen C.L., Chan E., Turner D.S., Iravani M., Nagy M., Selam J.L., et al. Insulinantibody responses after long-term intraperitoneal insulin administrationvia implantable programmable insulin delivery systems. Diabetes Care 1994, 17:169-176.
51. Jeandidier N., Boivin S., Sapin R., Rosart-Ortega F., Uring-Lambert B., Reville P., et al. Immunogenicity of intraperitoneal insulin infusionusing programmable implantable devices. Diabetologia 1995, 38:577-584.
52. Lassmann-Vague V., Belicar P., Raccah D., Vialettes B., Sodoyez J.C., Vague P. Immunogenicity of long-term intraperitoneal insulin administration with programmable pumps: metabolic consequences. Diabetes Care 1995, 18:498-503.
53. Kessler L., Tritschler S., Bohbot A., Sigrist S., Karsten V., Boivin, et al. Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump. Diabetes Care 2001, 24:302-307.
54. Jeandidier N., Boullu S., Busch-Brafin M.S., Chabrier G., Sapin R., Gasser F., et al. Comparison of antigenicity of Hoechst 21 PH insulin infusion using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients. Diabetes Care 2002, 25:84-88.
55. Lassmann-Vague V., Belicar P., Alessis C., Raccah D., Vialettes B., Vague P. Insulin kinetics in type 1 diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies. Diabet Med 1996, 13:1051-1055.
56. Saudek C.D., Duckworth W.C., Giobbie-Hurder A., Henderson W.G., Henry R.R., Kelley D.E. Implantable insulin pump vs multiple dose insulin for non-insulin dependent diabetes mellitus: a randomized clinical trial. JAMA 1996, 276:1322-1327.
57. Witkowski C.J., Saudek C. The implantable peritoneal pump-a patient's perspective. J Diabetes Sci Technol 2008, 2:703-706.
58. Lassmann-Vague V., Guerci B., Hanaire-Broutin H., Pinget M., Renard E., Selam J.L., et al. Use of implantable insulin pumps: the EVADIAC position. Diabete Metab 1997, 23:242-250. On behalf of the EVADIAC group.
59. Renard E., Schaepelynck-Bélicar P. Implantable insulin pumps: a position statement about their clinical use. Diabetes Metab 2007, 33:158-166. On behalf of the EVADIAC Group.
60. Renard E., Costalat G., Chevassus H., Bringer J. Artificial ß-cell clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab 2006, 32:497-502.
61. Renard E., Place J., Cantwell M., Chevassus, Palerm M.L. Closed-loop insulin delivery using a suscutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care 2010, 33:121-127.